Is Cervical Dystonia Holding You Back?

XEOMIN May Help Provide Relief

Designed For Purity, XEOMIN Has Only The Ingredients
It Needs To Deliver Results

What is Cervical Dystonia?

Cervical dystonia is a movement disorder causing involuntary muscle contractions in the neck that may twist and turn your head into uncomfortable positions. Symptoms may include painful muscle spasms, a tilted or rotated head, and the frustration of not being able to control your own movements.

Examples of Abnormal Postures

cd head tilting forward

Head tilts forward

cd head tilting back

Head tilts backwards

cd head rotates

Head rotates to left or
right side

cd head tilting to the side

Head tilts to the side

Images are for illustration purposes only. Individual results may vary.

* Cervical dystonia is the most common form of focal dystonia
* Estimated to affect more than 60,000 people in the United States in 20231

What is XEOMIN?

  • XEOMIN is an FDA-approved prescription medication that is used to treat adult upper limb spasticity

  • XEOMIN is a botulinum toxin type A, which may help decrease muscle contractions and neck pain.2

  • XEOMIN is injected by your doctor

cd patient image for cool water background

It became more painful to me, and obvious to others who pointed out that my head was tilted. It’s frustrating losing control of my own body.

45 year old

Not an actual patient.

How Does XEOMIN Work?

XEOMIN works by blocking the signals your nerves send to the muscles in your arm, so that these muscles can relax and not be as tight. This can improve your ability to move those muscles.
Patients typically start to see results one week after they start treatment with XEOMIN.
In clinical trials, most patients were retreated after 12 to 14 weeks.

Where is XEOMIN Injected?

xeomin single bottle
Where Is
XEOMIN
Injected?

Your doctor will locate certain areas of the neck and shoulders and inject XEOMIN directly into those areas. If needed, retreatment with XEOMIN can occur every
12 weeks.

You and your doctor can decide the right plan for you.

Possible Muscles Involved

dystonian lateral v2 desktop

Markings show examples of muscles that may be treated for cervical dystonia in adults; however, not all possible injection locations are shown. Not all patients will receive treatment in the same muscle(s). Your doctor will determine the appropriate locations and doses for XEOMIN injection.

cervical dystonia sitting patient

Not an actual patient.

How Can XEOMIN Help You?

In clinical studies, XEOMIN was shown to reduce symptoms associated with adult cervical dystonia, including abnormal neck position and neck pain.

48%

(322/669)

of patients experienced a meaningful decrease in pain† after their first XEOMIN injection

†Greater than 30% pain reduction = meaningful decrease in pain.

10%

(69/669)

of patients experienced complete pain relief after their first treatment with XEOMIN§

§The analyses in this study were based on patients who had a baseline pain assessment and reported experiencing pain at baseline. Because several studies with different designs were combined for this analysis, it was not possible to compare pain responses of patients receiving XEOMIN with those patients receiving placebo or a different comparator drug in their first injection cycle. Individual results may vary.

Designed For Purity, XEOMIN Has Only The Ingredients
It Needs To Deliver Results

Designed For Purity, XEOMIN Has Only The Ingredients
It Needs To Deliver Results

xtract technology logo with r1
XTRACT Technology is a state-of-the-art manufacturing process that removes the unnecessary proteins.
XEOMIN is uniquely purified to contain only the therapeutic component. It utilizes XTRACT Technology®, a state-of-the-art manufacturing process that removes unnecessary proteins, and makes XEOMIN different from other treatments.*
Repeated exposure to neurotoxins with complexing proteins may cause a person to develop antibodies to treatment, which may result in the treatments not working as well as they once did.†
Botulinum toxin type A with unnecessary proteins
XTRACT Technology
is a state-of-the-art manufacturing process 
that removes the unnecessary proteins
Leaving just the active therapeutic component†
The most common side effects in clinical trials of XEOMIN in adults
with cervical dystonia were:
Difficulty Swallowing|
Neck Pain|
Muscle Weakness
Pain at the Injection Site|
Muscle and Bone Pain

This information is not meant to imply superiority of safety or efficacy of any toxin. 

†It’s possible to develop antibodies with all botulinum toxins, including XEOMIN.

background
Move Forward with XEOMIN, a Uniquely Purified Option for Cervical Dystonia
cd move forward patient with doctor

XEOMIN has been proven safe and effective and used in 6.5 million patients from more than 75 countries, for more than 12 years.

Not an actual patient. Individual results may vary.

cd move forward
Move Forward with XEOMIN, a Uniquely Purified Option for Cervical Dystonia

XEOMIN has been proven safe and effective and used in 6.5 million patients from more than 75 countries, for more than 12 years.

Not an actual patient. Individual results may vary.

Support to Help You Start and Stay on Xeomin

Patient
Savings Program

Eligible commercially insursed patients

Save up to $5,000 annually*

Start Saving Now

Visit MERZCONNECT.com for additional information to help you
get started and stay on XEOMIN.

XEOMIN Patient Savings is
Available in Just 3 Easy Steps.

  1. Enroll in the program*

  2. Receive XEOMIN treatment

  3. Obtain program savings*†

*Restrictions apply to eligibility. Commercial insurance required.

Reimbursement limited to out-of-pocket XEOMIN medication costs and related administration fees. State limitations may apply. Please see Full Terms and Conditions at MERZCONNECT.com. Merz reserves the right to change XEOMIN Patient Savings Program Terms and Conditions, including the eligibility requirements, at any time. This is not health insurance.

†You may be required to pay upfront for your co-pay/co-insurance, as determined by your insurance coverage/policy and your healthcare provider’s co-pay collection practice.

Once you and your doctor have decided XEOMIN is right for you, MERZ CONNECT offers you savings and support to help you get started and stay on therapy.

reclaim moments

Reclaim Life’s Moments
with XEOMIN

If You’re New to Treatment, or Your Current or Past Therapy isn’t Working as Well As it Used to, Talk to Your Doctor Today!

Reclaim Life’s Moments
with XEOMIN

If You’re New to Treatment, or Your Current or Past Therapy isn’t Working as Well As
it Used to, Talk to Your Doctor Today!

References

  1. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/cervical-dystonia/#affected. Accessed June 2024.
  2. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2023.
IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING
WARNING:
DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete BOXED WARNING.

The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

INDICATIONS

XEOMIN® (incobotulinumtoxinA) for injection is indicated for the treatment of:

  • Chronic sialorrhea in patients 2 years of age and older
  • Upper limb spasticity in adults
  • Upper limb spasticity in pediatric patients 2 years of age and older, excluding spasticity caused by cerebral palsy
  • Cervical dystonia in adults
  • Blepharospasm in adults
CONTRAINDICATIONS
  • Known hypersensitivity to any botulinum toxin product or to any of the components in the formulation.
  • Infection at the proposed injection site(s) because it could lead to severe local or disseminated infection.
WARNINGS AND PRECAUTIONS
  • The potency units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products.
  • Serious hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of XEOMIN and institute appropriate medical therapy immediately. The use of XEOMIN in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.
  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia [See BOXED WARNING].
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) may be at increased risk for severe dysphagia and respiratory compromise from typical doses of XEOMIN.
  • Caution should be taken when XEOMIN is used where the targeted muscle shows excessive weakness or atrophy.
  • Cervical Dystonia: Treatment with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post- marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products. Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.
  • Blepharospasm: Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. To decrease the risk for ectropion, XEOMIN should not be injected into the medial lower eyelid area.
  • XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been reported for albumin.
ADVERSE REACTIONS

The most commonly observed adverse reactions at rates specified below and greater than placebo are:

  • Chronic Sialorrhea:
    • in adults (≥4% of patients): tooth extraction, dry mouth, diarrhea, and hypertension.
    • in pediatric patients (≥1% of patients): bronchitis, headache, and nausea/vomiting.
  • Upper Limb Spasticity
    • in adults (≥2% of patients): seizure, nasopharyngitis, dry mouth, and upper respiratory tract infection.
    • in pediatric patients (≥3% of patients): nasopharyngitis and bronchitis.
  • Cervical Dystonia in adults (≥5% of patients): dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.
  • Blepharospasm in adults (≥10% of patients): eyelid ptosis, dry eye, visual impairment, and dry mouth.
DRUG INTERACTIONS

Co-administration of XEOMIN and aminoglycoside or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.

Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects.

The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

USE IN PREGNANCY

There are no adequate data on the developmental risk associated with the use of XEOMIN in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE

Safety and effectiveness of XEOMIN in patients less than 18 years of age have not been established for lower limb spasticity, cervical dystonia, or blepharospasm. Safety and effectiveness have been established in pediatric patients 2 to 17 years of age in patients with chronic sialorrhea and upper limb spasticity. A pediatric assessment for XEOMIN in upper limb spasticity demonstrates that XEOMIN is safe and effective in another pediatric population. However, XEOMIN is not approved for such patient population due to marketing exclusivity for another botulinum toxin.

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING
WARNING:
DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete BOXED WARNING.

The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

INDICATIONS

XEOMIN® (incobotulinumtoxinA) for injection is indicated for the treatment of:

  • Chronic sialorrhea in patients 2 years of age and older
  • Upper limb spasticity in adults
  • Upper limb spasticity in pediatric patients 2 years of age and older, excluding spasticity caused by cerebral palsy
  • Cervical dystonia in adults
  • Blepharospasm in adults
CONTRAINDICATIONS
  • Known hypersensitivity to any botulinum toxin product or to any of the components in the formulation.
  • Infection at the proposed injection site(s) because it could lead to severe local or disseminated infection.
WARNINGS AND PRECAUTIONS
  • The potency units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products.
  • Serious hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of XEOMIN and institute appropriate medical therapy immediately. The use of XEOMIN in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.
  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia [See BOXED WARNING].
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) may be at increased risk for severe dysphagia and respiratory compromise from typical doses of XEOMIN.
  • Caution should be taken when XEOMIN is used where the targeted muscle shows excessive weakness or atrophy.
  • Cervical Dystonia: Treatment with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post- marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products. Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.
  • Blepharospasm: Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. To decrease the risk for ectropion, XEOMIN should not be injected into the medial lower eyelid area.
  • XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been reported for albumin.
ADVERSE REACTIONS

The most commonly observed adverse reactions at rates specified below and greater than placebo are:

  • Chronic Sialorrhea:
    • in adults (≥4% of patients): tooth extraction, dry mouth, diarrhea, and hypertension.
    • in pediatric patients (≥1% of patients): bronchitis, headache, and nausea/vomiting.
  • Upper Limb Spasticity
    • in adults (≥2% of patients): seizure, nasopharyngitis, dry mouth, and upper respiratory tract infection.
    • in pediatric patients (≥3% of patients): nasopharyngitis and bronchitis.
  • Cervical Dystonia in adults (≥5% of patients): dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.
  • Blepharospasm in adults (≥10% of patients): eyelid ptosis, dry eye, visual impairment, and dry mouth.
DRUG INTERACTIONS

Co-administration of XEOMIN and aminoglycoside or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.

Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects.

The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

USE IN PREGNANCY

There are no adequate data on the developmental risk associated with the use of XEOMIN in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE

Safety and effectiveness of XEOMIN in patients less than 18 years of age have not been established for lower limb spasticity, cervical dystonia, or blepharospasm. Safety and effectiveness have been established in pediatric patients 2 to 17 years of age in patients with chronic sialorrhea and upper limb spasticity. A pediatric assessment for XEOMIN in upper limb spasticity demonstrates that XEOMIN is safe and effective in another pediatric population. However, XEOMIN is not approved for such patient population due to marketing exclusivity for another botulinum toxin.